文献速递膀胱癌与上尿路尿路上皮癌

新辅助化疗对高危上尿路尿路上皮癌病理分期的影响比较

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
PubMed 文献 · J Urol · 2018-01-04

该回顾性研究纳入2003至2017年约翰霍普金斯医院240例上尿路尿路上皮癌患者,其中32例接受新辅助化疗后行根治性肾输尿管切除术,208例仅手术。新辅助化疗组病理分期显著更低,pT2及以上比例37.5% vs 59.6%(p=0.02),无临床淋巴结阳性或低体积转移患者中pT3及以上比例降低46.5%(25.9% vs 48.4%,p=0.04),完全缓解率9.4%。

要点

  • 高危上尿路尿路上皮癌新辅助化疗后病理分期显著降低(p<0.001)。
  • 新辅助化疗组pT2及以上比例显著低于单纯手术组(37.5% vs 59.6%,p=0.02)。
  • 无临床淋巴结阳性或低体积转移患者中pT3及以上比例降低46.5%(p=0.04)。

核心结论

  • 高危上尿路尿路上皮癌患者接受新辅助化疗后病理分期分布低于单纯根治性肾输尿管切除术患者。

研究设计与样本

  • 回顾性分析约翰霍普金斯医院2003至2017年240例上尿路尿路上皮癌患者,研究组32例接受新辅助化疗,对照组208例仅手术。

主要发现

  • 新辅助化疗组病理分期显著更低(p<0.001)。
  • 新辅助化疗组pT2及以上比例37.5%,对照组59.6%(p=0.02)。
  • 无临床淋巴结阳性或低体积转移患者中,新辅助化疗组pT3及以上比例25.9%,对照组48.4%(p=0.04),降低46.5%。
  • 新辅助化疗组完全缓解率9.4%。

临床怎么用

  • 对于活检证实高级别且影像学可见病灶的高危上尿路尿路上皮癌患者,可考虑在根治性肾输尿管切除术前给予新辅助化疗以降低病理分期。

局限性

  • 回顾性研究,样本量有限(研究组32例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High risk upper tract urothelial carcinoma has been associated with poor survival outcomes. Limited retrospective data support neoadjuvant chemotherapy prior to radical nephroureterectomy. To validate prior findings we evaluated differences in the pathological stage distribution in patients with high risk upper tract urothelial carcinoma based on the administration of neoadjuvant chemotherapy before radical nephroureterectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of 240 patients with upper tract urothelial carcinoma at The Johns Hopkins Hospital from 2003 to 2017. Patients with biopsy proven high grade disease and a visible lesion on cross-sectional imaging were offered neoadjuvant chemotherapy prior to radical nephroureterectomy. A control group of a time matched cohort of patients with biopsy proven high grade disease underwent extirpative surgery alone. The chi-square and Fisher exact tests were used to evaluate clinical and pathological variables between the cohorts. RESULTS: There were 32 patients in the study group and 208 in the control group. Significantly lower pathological stage was noted in the study group than in the control group (p <0.001). Significantly fewer patients with pT2 disease or higher were treated with neoadjuvant chemotherapy (37.5% vs 59.6%, p = 0.02). There was a 46.5% reduction in the prevalence of pT3 disease or higher in study group patients without clinically node positive or low volume metastatic disease (25.9% vs 48.4%, p = 0.04). A 9.4% complete remission rate was observed in patients who underwent neoadjuvant chemotherapy. CONCLUSIONS: Patients with high risk upper tract urothelial carcinoma treated with neoadjuvant chemotherapy were noted to have a lower pathological stage distribution than patients treated with radical nephroureterectomy alone.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Liao RS, Gupta M, Schwen ZR, et al. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol. 2018. PMID: 29307680. doi:10.1016/j.juro.2017.12.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。